EBCC 2024
Interviews and expert commentary from EBCC 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.

Audio Journal of Oncology
Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC
28 August 2025
15:48